On Oct 31, major Wall Street analysts update their ratings for $Penumbra (PEN.US)$, with price targets ranging from $232 to $248.
Baird analyst David Rescott maintains with a buy rating, and adjusts the target price from $180 to $248.
Needham analyst Michael Matson maintains with a hold rating.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and adjusts the target price from $222 to $232.
Piper Sandler analyst Matthew O'Brien maintains with a buy rating, and adjusts the target price from $225 to $235.
Truist Financial analyst Richard Newitter maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Penumbra (PEN.US)$'s main analysts recently are as follows:
Following the company's third-quarter earnings surpassing expectations, it's noted that the completion of the THUNDER trial enrollment and the FDA clearance of two new CAVT products, Lightning Bolt 6X and 12, position the company well for future growth. The potential for innovation in a market that has not been fully tapped is anticipated to fuel Penumbra's continued revenue growth in double digits and contribute to significant improvements in profit margins.
The firm expressed that the third quarter revenue and operating margin beat has bolstered confidence in meeting the revised full-year guidance for 2024 and the anticipated acceleration of growth in 2025, which they believe is crucial for the stock's upward trajectory.
Here are the latest investment ratings and price targets for $Penumbra (PEN.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月31日，多家华尔街大行更新了$Penumbra (PEN.US)$的评级，目标价介于232美元至248美元。
贝雅分析师David Rescott维持买入评级，并将目标价从180美元上调至248美元。
Needham分析师Michael Matson维持持有评级。
加皇资本市场分析师Shagun Singh Chadha维持买入评级，并将目标价从222美元上调至232美元。
派杰投资分析师Matthew O'Brien维持买入评级，并将目标价从225美元上调至235美元。
储亿银行分析师Richard Newitter维持买入评级。
此外，综合报道，$Penumbra (PEN.US)$近期主要分析师观点如下：
公司第三季度收益超出预期，值得注意的是，完成了THUNDER试验的招募工作，并获得了FDA对两款新的CAVt产品——闪电6X和12的清算，为公司未来的增长做好了准备。在一个尚未完全开发的市场中进行创新的潜力被预计将推动penumbra持续保持两位数的营业收入增长，并有助于利润率的显著改善。
公司表示，第三季度的营业收入和营业利润率的超过强化了对能够满足2024年全年修订指引以及2025年增长预期的信心，他们认为这对股票的上升轨迹至关重要。
以下为今日5位分析师对$Penumbra (PEN.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
